Ingredient deep-dive

The Six-Year Ginkgo Trial Nobody Quotes

Three thousand and sixty-nine older adults took a standardised ginkgo extract twice a day for a median of six years, and it did not reduce dementia incidence. That is the largest and longest test this plant has ever been given, it is almost never mentioned on a label that contains it, and everything else written about ginkgo has to be read against it.

By Primal Grow Pro Team · Last updated October 29, 2026 · 9 min read · Ingredient deep-dive · Reviewed by Dr. Jonathan Clavell, MD

The trial that ran for six years

The single most informative piece of ginkgo research is also the one least likely to appear in marketing material.

The GEM trial recruited 3,069 older adults and gave them 120 mg of a standardised extract twice a day, or placebo, for a median of 6.1 years. The endpoint was dementia incidence. The result was that ginkgo did not reduce it.

Three things make that finding heavy. It is enormous by the standards of botanical research. It ran for over six years, which is longer than almost anything in this field. And it used the dose and the preparation that the literature had converged on, so it is not a study that can be dismissed as having tested the wrong thing.

A positive result on that trial would have been extremely hard to miss. Its absence is the single most important piece of context for any claim made about this plant, and a page quoting ginkgo trials without mentioning it is presenting a selection rather than a summary.

Five entries. Note the split doses: the figure people quote as 120 mg is usually one half of a twice-daily regimen rather than a whole day's intake.

Where the 120 mg figure came from

Ask most people in this category where the ginkgo dose comes from and they will say 120 mg. That figure is real, it comes from the clinical literature, and it is usually being quoted incorrectly.

The NIH LiverTox monograph describes typical oral use as 120 to 240 mg a day, given in two or three divided doses. The 120 mg that circulates as a headline number is frequently one half of a twice-daily regimen, which makes the day’s intake 240 mg.

That distinction matters for a once-daily product in a way it does not for a twice-daily one. A capsule taken once, even at a matching daily total, is not the regimen the trials ran. Whether that changes the outcome is a fair question and it has not been answered, because nobody has run the comparison.

The word doing the most work: standardised

Ginkgo leaf is not the ingredient in the trials. The ingredient is an extract, prepared to fixed percentages of two classes of compound: flavone glycosides and terpene lactones. The best-studied preparations hold those percentages constant from batch to batch, which is what makes a trial result transferable to a later bottle at all.

So a label naming only the plant has left out what the research depends on. Two products both carrying 120 mg of a ginkgo extract can differ in the compounds the literature credits, and nothing on either front panel would show it.

NCCIH’s summary of ginkgo is a reasonable general starting point for a reader who wants a neutral overview of what has and has not been established.

What that means for a combination formula

In a seven-ingredient capsule the standardisation question is usually unanswerable, because combination products rarely specify it even when they specify amounts. A buyer comparing a combination with a trial is comparing a name with a preparation, and those are not the same kind of object.

The rest of the cognitive literature

GEM asked a prevention question in people who did not have dementia. A separate body of work asks a treatment question in people who do, and it is the one the 2026 Cochrane review of ginkgo for cognitive impairment and dementia synthesises.

Cochrane reviews are worth reading rather than summarising, and the honest one-line version is that the modern syntheses in this area are cautious. That caution is itself the useful finding: a plant with this much research behind it and this little consensus is telling you the effect, if present, is small.

The population point recurs throughout. Most of the cognitive work sits in older adults with measurable impairment. A healthy forty-five-year-old wanting sharper afternoons is not the person those trials recruited, and the result does not transfer to them in either direction.

The circulation evidence, which is different

Ginkgo’s circulation literature is separate from its cognitive literature and it is in better shape, in the narrow sense that it found something.

The Cochrane review of ginkgo for intermittent claudication pooled fourteen trials in people whose leg circulation was impaired enough to cause pain on walking. It reported a difference in pain-free walking distance that was small and of uncertain clinical importance.

That is a genuine finding and it is also a narrow one. The participants had a diagnosed circulatory problem, the measure was a walking test, and the effect was modest. Reading it as support for a general circulation claim in healthy adults stretches it a very long way.

It does explain, honestly, why ginkgo appears on a label that names circulation as one of its supports. There is a literature there. It is just not a literature about the person buying the bottle.

Ginkgo and sexual function, which is different again

Ginkgo turns up in male vitality formulas partly on the strength of a small sexual-function literature, and that literature is worth knowing about because it is mostly negative.

A systematic review of clinical trials on ginkgo and sexual function collects what exists. The controlled trials in this area, including work in people whose sexual dysfunction was caused by antidepressant medication, did not show ginkgo performing better than placebo.

The open-label reports that generated the original interest looked more promising, which is a familiar pattern: an uncontrolled observation produces enthusiasm and a controlled trial does not confirm it. That sequence is the reason controlled trials exist.

So a ginkgo row in a vitality formula is best read as a circulation row rather than a sexual-function one, and even then with the population caveat attached.

The bleeding question, in proportion

Ginkgo has a reputation for interacting with blood-thinning medicines, and the reputation is stronger than the evidence.

The concern rests on case reports and on a plausible mechanism involving platelet activating factor. Reviews that have examined it carefully tend to conclude that the evidence for a clinically important interaction is weaker than the warnings imply.

Weak evidence of harm is not evidence of safety, which is why the practical advice does not change: anybody on an anticoagulant or a platelet inhibitor, and anybody with surgery booked, should say what they are taking. The conversation costs nothing and the alternative is a small unnecessary risk.

How to read a ginkgo row on any label

Five things that turn a ginkgo row into something checkable. A label carrying the name alone carries none of them.

Five things, and a label carrying all five is unusual enough to be worth noticing. Most carry one or two. A row reading “Ginkgo Biloba Extract (leaf), standardised to 24% flavone glycosides and 6% terpene lactones, 120 mg” is a company telling you it knows which literature it is borrowing from.

And what to do when the row is just a name

• Take the name seriously anyway. Knowing ginkgo is present is genuinely useful for the interaction question, whatever the amount.
• Do not transfer the trial result. A name is not a dose and a dose is not a preparation. The GEM figure belongs to GEM.
• Ask the seller the five questions in the table above. They are reasonable and the answers are informative whatever they are.
• Weigh the refund terms more heavily. Where nothing can be verified before purchase, the ability to undo it is the practical substitute.
• Judge it on your own eight weeks. With no figure to compare against, your own measurements are better evidence about your own experience than any trial in this post.
• And remember the largest trial was negative. Expect something subtle or nothing at all, which is what the literature supports.

None of that is a reason to dismiss ginkgo. It is one of the most studied plants in commerce, its safety record in ordinary use is good, and its circulation literature found something real in the population it looked at. It is a reason to be precise about what the number on a label means, and to notice when there is no number at all. The ingredients page sets out what this particular label carries.

References